MTOR and neoplasm: These results indicate that the AMPK activator metformin potentiates the anti-tumor effect of niclosamide for FAP patients through the suppression of canonical Wnt and mTOR activity as well as by the activation of the tumor suppressive Hippo pathway (Figure 4F).